ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Supriya Lifescience Ltd reported revenue from operations of ₹276.5 Cr (+50.2% YoY) and net profit of ₹74.2 Cr (+47.2% YoY) for Q4 FY26.
Supriya Lifescience reported a ₹209.12 Crore annual net profit for FY26. The board also recommended a final dividend of ₹1 per equity share.
Supriya Lifescience scheduled a board meeting on May 27, 2026. Directors will consider audited financial results and recommend a potential dividend for fiscal year 2026.
Supriya Lifescience Ltd informed exchanges that it does not qualify as a 'Large Corporate' per SEBI criteria for FY 2026-27. The company reported nil outstanding borrowings and an A+ credit rating from India Ratings. This disclosure confirms compliance with debt-market borrowing framework requirements.
Supriya Lifescience Ltd successfully completed a USFDA inspection at its Lote manufacturing facility. The inspection, conducted in February 2026, concluded with one minor observation and the receipt of an Establishment Inspection Report (EIR) indicating Voluntary Action Indicated (VAI) status. This confirms the facility's compliance with current Good Manufacturing Practice (cGMP) standards.
Supriya Lifescience Limited announced the passing of three special resolutions via postal ballot with requisite majority. Shareholders approved the appointments of Mr. Manish Panchal and Mr. Kothandaraman Hari, and the re-appointment of Dr. Neelam Arora, as Non-Executive Independent Directors for five-year terms.